参考文献/References:
[1] Morton AC,Rothman AM,Greenwood JP,et al.The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes:the MRC-ILA Heart Study[J].Eur Heart J,2015,36(6):377-384.
[2] Ridker PM,Howard CP,Walter V,et al.Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c,lipids,C-reactive protein,interleukin-6,and fibrinogen:a phaseⅡb randomized, placebo-controlled trial[J].Circulation,2012, 126(23):2739-2748.
[3] Ridker PM,Thuren T,Zalewski A,et al.Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events:rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study(CANTOS)[J].Am Heart J,2011,162(4):597-605.
[4] Padfield GJ,Din JN,Koushiappi E,et al.Cardiovascular effects of tumour necrosis factor alpha antagonism in patients with acute myocardial infarction:a first in human study[J].Heart,2013,99(18):1330-1335.
[5] Mohler ER, Ballantyne CM, Davidson MH, et al.The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent:the results of a multicenter, randomized, double-blind, placebo-controlled study[J].J Am Coll Cardiol,2008,51(17):1632-1641.
[6] Serruys PW,Garcia-Garcia HM,Buszman P,et al.Effects of the direct lipoprotein-associated phospholipase A(2)inhibitor darapladib on human coronary atherosclerotic plaque[J].Circulation,2008,118(11):1172-1182.
[7] Garcia-Garcia HM,Klauss V, Gonzalo N,et al. Relationship between cardiovascular risk factors and biomarkers with necrotic core and atheroma size: a serial intravascular ultrasound radiofrequency data analysis[J].Int J Cardiovasc Imaging, 2012,28(4):695-703.
[8] Garcia-Garcia HM,Oemrawsingh RM,Brugaletta S,et al.Darapladib effect on circulating high sensitive troponin in patients with acute coronary syndromes[J].Circ J,2013,77(6):1518-1525.
[9] White HD,Held C,Stewart R.Darapladib for preventing ischemic events in stable coronary heart disease[J].N Engl J Med,2014,370(18):1702-1711.
[10] O'Donoghue ML,Braunwald E,White HD,et al.Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial[J].JAMA,2014,312(10):1006-1015.
[11] Koenig W, Khuseyinova N.Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence[J].Cardiovasc Drugs Ther, 2009,23(1):85-92.
[12] Rosenson RS, Hislop C,Elliott M,et al.Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients[J]. J Am Coll Cardiol,2010,56(14):1079-1088.
[13] Rosenson RS,Fraser H,Goulder MA,et al.Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome[J].Cardiovasc Drugs Ther,2011,25(6):539-544.
[14] Rosenson RS,Elliott M,Stasiv Y,et al.Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease[J].Eur Heart J,2011,32(8):999-1005.
[15] Dzavik V,Lavi S,Thorpe K,et al.The sPLA2 Inhibition to Decrease Enzyme Release after Percutaneous Coronary Intervention(SPIDER-PCI)trial[J].Circulation,2010,122(23):2411-2418.
[16] Lavi S,Thorpe K,Luca MC,et al.Inhibition of sPLA2 and endothelial function: a substudy of the SPIDER-PCI trial[J].Can J Cardiol,2012,28(2):215-221.
[17] Nicholls SJ,Kastelein JJ,Schwartz GG,et al.Varespladib and cardiovascular events in patients with an acute coronary syndrome:the VISTA-16 randomized clinical trial[J].JAMA,2014,311(3):252-262.
[18] Newby LK,Marber MS,Melloni C,et al. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial[J].Lancet,2014,384(9949):1187-1195.
[19] O'Donoghue ML,Glaser R,Aylward PE,et al.Rationale and design of the Losmapimod to inhibit p38 MAP kinase as a therapeutic target and modify outcomes after an acute coronary syndrome trial[J].Am Heart J,2015,169(5):622-630.
[20] Micha R,Imamura F,Wyler von Ballmoos M,et al.Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease[J].Am J Cardiol,2011,108(9):1362-1370.
[21] Landewe RB,van den Borne BE,Breedveld FC,et al.Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity[J]. Lancet, 2000, 335(9215):1616-1617.
[22] Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial(CIRT)[J]. J Thromb Haemost,2009,7(1):332-339.
[23] Nidorf SM, Eikelboom JW, Budgeon CA, et al.Low-dose colchicine for secondary prevention ofcardiovascular disease[J]. J Am Coll Cardiol,2013,61:404-410.
[24] Deftereos S,Giannopoulos G,Raisakis K,et al.Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients[J].J Am Coll Cardiol, 2013, 61(16):1679-1685.
[25] Giannopoulos G,Angelidis C,Kouritas VK,et al.Usefulness of colchicine to reduce perioperative myocardial damage in patients who underwent on-pump coronary artery bypass grafting[J].Am J Cardiol,2015,115(10):1376-1381.
[26] Tardif JC, Tanguay JF, Wright SS,et al.Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial[J]. J Am Coll Cardiol,2013,61(20):2048-2055.
[27] Tardif JC,L'Allier PL,Ibrahim R,et al.Treatment with 5-lipoxygenase inhibitor VIA-2291(Atreleuton)in patients with recent acute coronary syndrome[J].Circ Cardiovasc Imaging,2010,3(3):298-307.
[28] Gaztanaga J,Farkouh M,Rudd JH,et al.A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome[J]. Atherosclerosis,2015,240(1):53-60.
[29] Tardif JC,L'Allier PL,Gregoire J,et al.A randomized controlled, phase 2 trial of the viral serpin Serp-1 in patients with acute coronary syndromes undergoing percutaneous coronary intervention[J].Circ Cardiovasc Interv,2010,3(6):543-548.
[30] Varas-Lorenzo C,Riera-Guardia N,Calingaert B,et al.Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies[J].Pharmacoepidemiol Drug Saf,2013,22(6):559-570.
相似文献/References:
[1]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[2]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(1):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[3]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(1):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[4]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(1):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[5]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(1):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[6]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(1):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[7]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(1):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[8]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(1):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[9]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(1):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
[10]方砚 王效浣 郭朝霞.血流介导性血管扩张评价心血管病患者肱动脉内皮功能的研究进展[J].心血管病学进展,2019,(5):793.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.032]
FANG Yan,WANG Xiaohuan,GUO Zhaoxia.Flow- mediated Vasodilation Evaluation of Brachial Artery Endothelial Function in Patients with Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):793.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.032]